OR WAIT 15 SECS
Click here to read the articles and download the PDF
Deeply shaped by the experiences of his parents and an early charge to help drive social change, Global Blood Therapeutics’ Ted Love comes at sickle cell disease from a place of caring and urges pharma to follow suit to bring justice to all.
With a complicated and challenging global picture greeting the new year, driven by the continuing pandemic and historic political and regulatory changes in the US and Europe, we outline eight diverse trends critical to biopharma’s future health and growth.
A recent roundtable moderated by Rob Jekielek of The Harris Poll gathered five biopharma CEOs to discuss the industry’s shifting reputational landscape in the public eye.
Samit Hirawat, chief medical officer at Bristol Myers Squibb, talks about his leading role in BMS’ $300M, five-year plan to expand its efforts in health equity and his career-long commitment to putting patients first.
Click for more information and to submit a nomination
Highlighted Videos
January 27, 2021
Mark Altmeyer, CEO of Arvelle, offers three recommendations for big pharma executives who are considering making the leap to startups.
January 26, 2021
Report highlights how lung cancer progress in diagnosis has been pushed back, with further impact on treatment likely as the pandemic continues.
Patient Assistance Programs (PAPs) came out of the shadows in 2020 as several factors aligned that increased demand and awareness of these programs.
The pharmaceutical industry must be prepared for the coming wave of COVID-related safety reports.
January 25, 2021
President Joe Biden has unveiled a lengthy program for combatting COVID-19 by ramping up distribution and inoculation of millions of Americans over the next three months.
Exploring the importance of analytics as a means of staying competitive in the commercial pharmaceutical market.
January 21, 2021
Editorial Director, Lisa Henderson; European and online editor, Julian Upton; Senior Editor, Elaine Quilici ;and Assistant Editors of Pharmaceutical Executive, Miranda Schmalfuhs and Andy Studna, discuss some exciting industry trends for 2021, which they recently wrote for the January issue.
There is considerable variation in the regulatory approach to medical cannabis between European countries. Yet, despite the complexity, there are clear routes to market, reports Peter Kohut.
January 19, 2021
The process of distributing millions of doses of new vaccines across the nation has been much less effective than anticipated.
Week-long event aims to help commercialize innovations to reach patients in need.
January 18, 2021
How engaging with digital influencers holds the key for medical affairs.
January 15, 2021
Sameer Lal and Sandeep Gantotti discuss the building of a next-gen medical information practice to modernize its operations and unlock its value to the wider organization and to HCPs.
January 14, 2021
Administration officials continue to rush through new rules and decisions that appear to challenge the independence and effective operations of FDA.
How biopharma manufacturers can address extreme pricing of novel rare disease medicines and build legitimacy into commercialization to avoid an industrywide crisis.
Data suggests physicians just as hesitant as patients, but recent successes could turn the tide.
January 13, 2021
Industry’s tardy shift to cloud-based solutions looks set to gather pace in 2021.
Biopharma sustainability resolutions for a better 2021.
January 12, 2021
On December 24, 2020, the UK finally agreed a Trade and Cooperation Agreement (TCA) with the EU. Cliodhna McDonough offers some initial thoughts on the implications of the TCA on the life sciences sector.
Biden administration faces key decisions on drug testing and access amid vaccine distribution challenges.
Embracing the new, holistic views of pharma in 2021.
The need to prioritize digital skill-building companywide.
Looking back at 1981.
EU tasked with translating bold declarations into reality.
January 11, 2021
How PREP Act protections will apply to potential COVID-19 vaccine-related claims.
January 08, 2021
Panel will provide guidance around evolving digital business models.
Tone still set on the market catalysts to look for in 2021.
January 07, 2021
Gregg Beloff, co-founder of Danforth Advisors, discusses the banner year biotech IPOs had in 2020, the drive behind that boom, and what the future of industry IPOs might look like.
CDER's process for vetting and authorizing important new therapies remained strong and productive last year, despite the need to deal with COVID-19 related approvals and policies.
